Evidence map›Paper›PMID 39757733›Full record

Trial reportJournal of surgical oncology2025

Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer.

Nataliya V Uboha, Mustafa M Basree, Jens C Eickhoff, Dustin A Deming, Kristina Matkowskyj, James Maloney, Daniel McCarthy, Malcolm DeCamp, Noelle LoConte, Philip B Emmerich and 6 more

Abstract readClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nataliya V UbohaDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.ORCID http://orcid.org/0000-0003-3449-1680
Mustafa M BasreeDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Jens C EickhoffDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Dustin A DemingDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Kristina MatkowskyjWilliam S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA.
James MaloneyWilliam S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA.
Daniel McCarthyDivision of Cardiothoracic Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Malcolm DeCampDivision of Cardiothoracic Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Noelle LoConteDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Philip B EmmerichDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Sean KrausDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Monica A PatelDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Jeremy D KratzDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Sam J LubnerDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Newton HurstDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Michael F BassettiDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
BLRD VA IK2 BX006146NCI NIH HHS P30 CA014520This study was supported by University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520 and by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).
6 · The paper itself

Abstract

BACKGROUND AND

objectivesStandard treatment of patients with stage II/III esophageal or gastroesophageal junction (E/GEJ) cancer involves neoadjuvant chemoradiation (nCRT), resection, and immunotherapy. Our trial evaluated the addition of perioperative avelumab to standard treatments.

methodsPatients with resectable E/GEJ cancers received avelumab with nCRT and adjuvant avelumab after resection. Primary endpoints for phase I and II portions were safety and pathologic complete response (pCR) rate, respectively. Secondary endpoints included recurrence-free survival (RFS), surgical complication prevalence, and R0 resection rate.

resultsTwenty-two patients enrolled in the study. Median follow-up during data cutoff was 23.9 months. There were no dose-limiting toxicities during the run-in phase. Nineteen patients (86.4%) underwent resection with R0 resection rate of 78.9% and with pCR rate of 26%. Most common treatment-related adverse events (TRAE) were cytopenias from chemoradiation. Aside from one grade ≥ 3 avelumab-related hypersensitivity, no grade ≥ 3 avelumab TRAEs were seen. Median RFS was not reached, and 1-year RFS and overall survival were 71% and 81%, respectively. The study was terminated before full planned accrual due to standard practice change based on the CheckMate 577 trial.

conclusionsThe addition of perioperative avelumab to nCRT was tolerable and demonstrated promising outcomes.

Indexed as

AdenocarcinomaAntibodies, MonoclonalChemoradiotherapyEsophageal NeoplasmsEsophagogastric JunctionAdultAgedAntibodies, Monoclonal, HumanizedCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingAntibodies, MonoclonalAntibodies, Monoclonal, Humanizedavelumabchemoradiationesophageal cancergastroesophageal adenocarcinomaimmunotherapy

Identifiers

PMID39757733
PMCPMC12186108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.